series-c-plus
Stage
2
Investors
About
Dyne Therapeutics develops targeted therapies to treat muscle diseases using antibody conjugates to improve muscle delivery of antisense oligonucleotides and other therapeutic payloads.
Explore Dyne Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.